[{"title": "Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results - GlobeNewswire", "description": "<a href=\"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQa3lzYWVYc2hOOTRJazNJMmpINUQwcmZ5NlRXY2xpbjJHR3JMVl8wRndfWVpIT2lpbHhlN2pzMTZVN05QZDV2SDZOcnVpbHByYWRhZFE4WVpKYWF1S0pZMkVFSFZQMnpaU3JIU3BVLWxsZEt6TlpqUVd0Y0hna2l6c2tUYkJFSHpfMGZRekNlbVQ2c0V1NGNEQTFJbl9SOFFhQU5ST2NqRG9zSFd1MWNTUlJ0SWFwUmtuaUY0c09Bd2hEZVZwcnFZN1FYMU1uaHNZUnJMaGlXaGM3UGxFNHFMRlFkb1hzakxSOWMwdg?oc=5\" target=\"_blank\">Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">GlobeNewswire</font>", "publishedAt": "Wed, 13 Aug 2025 12:07:03 GMT"}, {"title": "Ovid Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView", "description": "<a href=\"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQVW5iUlNvcmVCdDdVY3hzRmRCWDR4ZnRDS0lQRjVMZDg1RnZjczV0NWprMzl1bzcxbmRBSDVrS0d4SFNIaUttTnJ5UjBZZUZCYU9qMFZaTDBDTWx6YlhJRkNtU2E2Y1JqWDNuaUU4TjctVFZLWlAwV09SaWNMMW1tVmRwM1ZTNjE3NFhYVEdJaE5EM3Bndmh2Uy1ERFZabVA2enZBcnBockREcXRBd2NlR09WWlBXVTllSFBscEJPc19WaTQ0alREemhVc3V2WDRhbG1fNE9FeTh6TC1JWWxwMHRZUkROLVFsT1E?oc=5\" target=\"_blank\">Ovid Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TradingView</font>", "publishedAt": "Wed, 13 Aug 2025 12:42:41 GMT"}, {"title": "Ovid Therapeutics Transfers Stock to Nasdaq Capital Market - The Globe and Mail", "description": "<a href=\"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNQnQwenRsWEVCUXdHZW03bC1MaV9XakVFbmF6TjlyR3NVQkdhcTM0akdxeEVsemo4OWN1LVQwTGpJdjNQVmM3SUVoVkVPaHBJbGlSNmhHNnUtbWlfMUZ4RHJObEVyZGtOeHRqOG1iYmxXaUUydFJhcHpnWVhBUVdRblc4bUwyNDM5QnRvSEx1OVY3TmxvczhuOURORVV0Yy1ydXhzc2lMV0cyUEptWDZkU3d4YlhsTEdxeER6WHRHUlAzWmE2aFpWcGNrUTM2MXREMGIzcVl6dWs5QXFhdUdn?oc=5\" target=\"_blank\">Ovid Therapeutics Transfers Stock to Nasdaq Capital Market</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Globe and Mail</font>", "publishedAt": "Thu, 14 Aug 2025 12:44:00 GMT"}, {"title": "Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results - Stock Titan", "description": "<a href=\"https://news.google.com/rss/articles/CBMivgFBVV95cUxPZ1BPODJZbWt6MTdsNE8xaTBjZVJuWmJFdThxV0hHd091dWp0cFFYVkV3Q25qcU02dFNWMGRSMmdoeE1jaW9FbU9ub05LM1NQUGQ5aGw3dHZhblFlVVMyVkluZmVPdXl5d2tROElBZXlzbHZlNW1pQlg1UGhJemRpdFBsTHlkWWw0MUpBRFp5eHJoMzNKYnFqMVBfdllMekFmZFltT2lhNXg4U2UzbEd1cy0tNGpnTlVJelpYYmRR?oc=5\" target=\"_blank\">Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Stock Titan</font>", "publishedAt": "Wed, 13 Aug 2025 12:00:00 GMT"}, {"title": "Ovid Therapeutics shares rise 34.92% intraday after reporting business updates and a $7.0 million royalty monetization agreement. - AInvest", "description": "<a href=\"https://news.google.com/rss/articles/CBMi4wFBVV95cUxPSG03TUl3YXdlYzE5NXJUWWRkM3lscnUyZkIzNy0xZjBSbmtOcl9qdVZBbW9LMDZxb0x0MG1PdkVOamRmWnV6WXdHOFA3SVRBdzBzd0dOYmJvZy1WMllsc3lxOHQtRUhkQ1l4dmxoZGdpQ2lsUWxQRE5xVTN6MDZHQWQxeVprU01ITE8ydHMyOVBXekNCYmlTZmFMRFNqdW5rdE1tZzNhSk9zSmxrTE9UZkEteDJZRXRLSl9HVjNLcnBJUmhYYUxZTzNTb1NlenpQdXU2Zk51QjdYYUdpQ19GYThKZw?oc=5\" target=\"_blank\">Ovid Therapeutics shares rise 34.92% intraday after reporting business updates and a $7.0 million royalty monetization agreement.</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">AInvest</font>", "publishedAt": "Wed, 13 Aug 2025 17:30:21 GMT"}, {"title": "Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating By Investing.com - Investing.com Nigeria", "description": "<a href=\"https://news.google.com/rss/articles/CBMiygFBVV95cUxNRW1LTHJRVVI1OGFvSFdybW5SV0hSTlRwYXg5WGF3LUlGTXJFc281ZWN6UUJiZF92UXVyN2VZTzIzN1JNSC11T1hreWVlakJYRHNzbTVWcUtsdG5GM1BOZlRlVUxMcUp4RXVRcTRzMDkyV3h3aU04MTUyREFPb1c4ZjBNMWhhbDF3THFyZnlLbzRTc0x5V1ZzcEd5c2FlVGJCWTJHQmJGNkNUWUgwbFpYWXVvLWp4MmppX2V0T1dvbU92VjBNQ1MwVWV3?oc=5\" target=\"_blank\">Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating By Investing.com</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investing.com Nigeria</font>", "publishedAt": "Wed, 13 Aug 2025 11:42:50 GMT"}, {"title": "Ovid Therapeutics Inc. SEC 10-Q Report - TradingView", "description": "<a href=\"https://news.google.com/rss/articles/CBMioAFBVV95cUxNQXJGTkFJMTY5U3FOTFVjUVhvQ3o3SlZ6enZvT2lBZHZuM0k0OFk2TGd4azBiLVE5V1h1WTBrd3NfRkExeHQxRi00N1E4WTMxVzZhUHM1Qm1vdjlXUzNpeVpDZjF6TFRFOHVBRHIweFpNU2VFVnhDeU1IRU5NSlVNc0c4VHdfQXJGYnZwWTdkTGlvRURGUUY2S3JGdXdqVTdG?oc=5\" target=\"_blank\">Ovid Therapeutics Inc. SEC 10-Q Report</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TradingView</font>", "publishedAt": "Wed, 13 Aug 2025 12:13:00 GMT"}, {"title": "Ovid Therapeutics Reports Increased Revenue Amid Challenges - TipRanks", "description": "<a href=\"https://news.google.com/rss/articles/CBMisAFBVV95cUxQZ1B2UGotMWRnc2EwcmRnN29KS1lLeEpWVkdOYVlZYU1fLW1TM0JwTWRVaERsQWpUb1ZRX0M0aGowN2tieXRWNC1tNmlULVROTEM0SUlwVjlERUN6dGhrVVJxeXFNMHBsV1JTbmMtUDJ4OUdpSGhmUmtSRENHbTZWWTlBa2tMM2Z5YjJEV1FCM3FZUGprNnczOEVyUUpFUGtINzhJSTZhM2o3NkhSZWl0Vg?oc=5\" target=\"_blank\">Ovid Therapeutics Reports Increased Revenue Amid Challenges</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TipRanks</font>", "publishedAt": "Thu, 14 Aug 2025 05:45:50 GMT"}, {"title": "Ovid Therapeutics Maintains Buy Rating with $3.00 Price Target from B.Riley Financial Analyst Madison Elsaadi. - AInvest", "description": "<a href=\"https://news.google.com/rss/articles/CBMiywFBVV95cUxNSmhsb1FhanVBVy1xeG5zYWh4d3U2VTZvd21pR0E3aWh6V1ZwQ2ZLUGwycXNHSjRxWkRGUHQxOW5KM3ozb0QtRVBRVTNLVkkyY0I0VWc4am44eDBRNU9JNjFWYXNyY1NhWnRZRXpNaG1pYl8wb2hKdVV0Zlk2NkZXcWUwd2pza2JiRHM5LU50VWFHUGFyT2tUdzYwRXktYm10dlhuNUZvaDVjV1ZBblU0TnJIUVBuMGFaOERNODR1NmsxR3pDcGJORHdLUQ?oc=5\" target=\"_blank\">Ovid Therapeutics Maintains Buy Rating with $3.00 Price Target from B.Riley Financial Analyst Madison Elsaadi.</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">AInvest</font>", "publishedAt": "Sat, 09 Aug 2025 10:26:42 GMT"}, {"title": "Is Ovid Therapeutics Inc. stock poised for growth - Free Watchlist for Low Risk High Return - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMihAFBVV95cUxOOWFWdVlCUXZENjJEazhBZm5BcHAyNVAzVXA1N1Q2VE5qbElSenVuaTN5Wnd3UlRXb2U5Rkw4TjNmS0pSVUNnOEQ1LWQ1R05SajBmYnhNTm5zWFJvanhJbHA0ck1DUU1hZ2hMUHVIcUNiVVhHZXE1TzluM2w0WHFHRTdIRzc?oc=5\" target=\"_blank\">Is Ovid Therapeutics Inc. stock poised for growth - Free Watchlist for Low Risk High Return</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Tue, 12 Aug 2025 01:04:59 GMT"}, {"title": "Tools to monitor Ovid Therapeutics Inc. recovery probability - Dividend Hike & Smart Money Movement Alerts - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMikwFBVV95cUxOLTVXUFQteEdHZTZtM0RkOGx2dTVSWU1sUXhIdkdRZ1dNZUw4cklwZVdEWWJ4SXNnQ3dNb05fSUNJV3o4S1B5UHB2YzhwcVlNTWJDc3ZXTHVvQTMtZWV2b2ZzV3VUZnV4RHZVSFV2Zk5tRHF6UzhoLWJMMUZ3aWprb1dUbEg4RE9qZGFZSTZyQ3l5TnM?oc=5\" target=\"_blank\">Tools to monitor Ovid Therapeutics Inc. recovery probability - Dividend Hike & Smart Money Movement Alerts</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Fri, 15 Aug 2025 02:53:40 GMT"}, {"title": "Ovid Therapeutics (NASDAQ:OVID) Trading Up 7.9% \u2013 Here\u2019s Why - Defense World", "description": "<a href=\"https://news.google.com/rss/articles/CBMinwFBVV95cUxQQzZ2aERhUGJIYlUwTk9Yc0RfOGVmVXF6clhQYXgzS09yMHJjWUxCUG1oVmMya0NZRnV4LV9ObFEyY0Vvc2tjUERlRkxqTmNDa3JJUHZXclBQUExmSDlVdzUtU3NMM0hWWVZJVE05Y1h4dFg5bGh1ME5XRk1iVExRZk84NXhxYUpjZTVRcnhhaUF2dUJ6VnVHLWlRd0VpSnc?oc=5\" target=\"_blank\">Ovid Therapeutics (NASDAQ:OVID) Trading Up 7.9% \u2013 Here\u2019s Why</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Defense World</font>", "publishedAt": "Tue, 12 Aug 2025 07:07:37 GMT"}, {"title": "Ovid Therapeutics (NASDAQ:OVID) Given Consensus Rating of \u201cBuy\u201d by Brokerages - Defense World", "description": "<a href=\"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPenFBUnBaZWtjODhGVXgtbFJUSHZrSU1NcUljUXhsYUY5MDdzSzNBOXhya1JrSjF6NkFGUExqRmtVeGhjTGpmUHc3bWp1Z1pHSGxUSkdNY1J1Y3NPYmgxZlppTDFLOG9ydEFMdHZpdk10ODA5MHZLSHVhMHFEYTAyZkcwMkNyNFJmNFJHZDRkRGd2WEx2XzUxUUtTN2tyVnlNT1BzVnc4UERmY2J0RHJ3N0h6dFVKXzVO?oc=5\" target=\"_blank\">Ovid Therapeutics (NASDAQ:OVID) Given Consensus Rating of \u201cBuy\u201d by Brokerages</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Defense World</font>", "publishedAt": "Wed, 13 Aug 2025 10:40:16 GMT"}]